Drug Trial Radar · NCT01631617
Effects of Treatments on Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 18, 2012
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Jun 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: \- To study the effect of eczema treatments on skin bacteria. Eligibility: * Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. * Healthy volunteers between 18 and 40 years of age with no history of eczema. Design: * Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed. * All participants will be assigned to one of several study groups. * Healthy volunteers must not have taken antibiotics in the year before the start of the study. * All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits. * Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.
Conditions
- Eczema
- Dermatitis
- Skin Diseases, Genetic
- Dermatitis, Atopic
- Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ)Drug
800/160 orally every 12 hours for 14 days
CephalexinDrug
500 mg orally every 8 hours for 14 days
DoxycyclineDrug
20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
Sodium hypochloriteOther
6 % dilute bleach
Placebo capsulesOther
Capsule orally every 8 hours daily for 14 days
Placebo Sodium hypochloriteOther
Three times a week for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize microbiome alterationsTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.